Abcellera Biologics Inc Revenue Growth Rates (ABCL), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Abcellera Biologics Inc   (NASDAQ: ABCL)
 

ABCL's Revenue Growth by Quarter and Year

Abcellera Biologics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ABCL/growth
https://api.csimarket.com/api/v1/companies/ABCL/fundamentals
https://api.csimarket.com/api/v1/companies/ABCL/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
ABCL Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 10.64
2nd Quarter June 4.05
1st Quarter March 8.32
FY 23.01

ABCLs Annual Revenue
Abcellera Biologics Inc 's Revenue in the fiscal year 2025 $ 75.13 millions
Abcellera Biologics Inc 's Revenue in the fiscal year 2024 $ 28.83 millions
Abcellera Biologics Inc 's Revenue in the fiscal year 2023 $ 38.03 millions
Abcellera Biologics Inc 's Revenue in the fiscal year 2022 $ 485.42 millions
Abcellera Biologics Inc 's Revenue in the fiscal year 2021 $ 375.20 millions




ABCL Revenue third quarter 2026 Y/Y Growth Comment
Abcellera Biologics Inc reported Revenue increase of 18.74% year on year in the third quarter 2026, to $ 10.64 millions, this is lower than Abcellera Biologics Inc 's recent average Revenue surge of 300.4%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 184 other companies have achieved higher Revenue growth. While Abcellera Biologics Inc ' s Revenue growth of 18.74% ranks overall at the positon no. 3871 in the third quarter 2026.


ABCL Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 18.74 %
2nd Quarter June -76.29 %
1st Quarter March 96.23 %
FY   -

Financial Statements
Abcellera Biologics Inc 's third quarter 2026 Revenue $ 10.64 millions ABCL's Income Statement
Abcellera Biologics Inc 's third quarter 2025 Revenue $ 8.96 millions Quarterly ABCL's Income Statement


ABCL Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 162.69 %
2nd Quarter June -51.32 %
1st Quarter March -81.45 %
FY (Year on Year)   -


Back to ABCL Growth rate Comparisons >> Back to ABCL Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #185
Healthcare Sector #547
Overall #3871

Revenue Y/Y Growth Statistics
High Average Low
4253.47 % 300.4 % -96.15 %
(Mar 31 2026)   (Dec 31 2023)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #185
Healthcare Sector #547
Overall #3871
Revenue Y/Y Growth Statistics
High Average Low
4253.47 % 300.4 % -96.15 %
(Mar 31 2026)   (Dec 31 2023)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Abcellera Biologics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
2429.25 % 199.58 % -86.37 %
(Dec 31 2021)  


ABCL's III. Quarter Q/Q Revenue Comment
Abcellera Biologics Inc achieved in the III. Quarter 2026 below company average Revenue doubling of 162.69% quarter on quarter, to $ 10.64 millions.

Although the III. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the -47.54% growth in the III. Quarter a year ago

Within Major Pharmaceutical Preparations industry 186 other companies have achieved higher Revenue quarter on quarter growth. While Abcellera Biologics Inc 's Revenue growth quarter on quarter, overall rank is 3696.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #187
Healthcare Sector #536
Overall #3696
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #187
Healthcare Sector #536
Overall #3696
Revenue Q/Q Growth Statistics
High Average Low
2429.25 % 199.58 % -86.37 %
(Dec 31 2021)  


ABCL's III. Quarter Q/Q Revenue Comment
Abcellera Biologics Inc achieved in the III. Quarter 2026 below company average Revenue doubling of 162.69% quarter on quarter, to $ 10.64 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -47.54% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 186 other companies have achieved higher Revenue quarter on quarter growth. While Abcellera Biologics Inc 's Revenue growth quarter on quarter, overall rank is 3696.


Abcellera Biologics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 67.86
Y / Y Revenue Growth (TTM) 92.11 %
Year on Year Revenue Growth Overall Ranking # 2683
Seqeuential Revenue Change (TTM) 2.54 %
Seq. Revenue Growth (TTM) Overall Ranking # 401


Cumulative Revenue growth Comment
Assuming the Abcellera Biologics Inc 's fiscal year would have ended in Sep 30 2026, Abcellera Biologics Inc would have reprted above average annual Revenue growth of 92.11% year on year, of $ 68 millions.
This marks a slow-down of the companys growth trends and from the 101.29% surge in Jun 30 2026.

In the Healthcare sector 382 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2683, from total ranking in previous quarter at 2984.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 54
Healthcare Sector # 383
Overall # 2683

Revenue TTM Y/Y Growth Statistics
High Average Low
242.68 %
 4.96 %
-92.17 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 54
Sector # 102
S&P 500 # 401
Cumulative Revenue growth Comment
Assuming the Abcellera Biologics Inc 's fiscal year would have ended in Sep 30 2026, Abcellera Biologics Inc would have reprted above average annual Revenue growth of 92.11% year on year, of $ 68 millions.
This marks a slow-down of the companys growth trends and from the 101.29% surge in Jun 30 2026.

In the Healthcare sector 382 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2683, from total ranking in previous quarter at 2984.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 54
Healthcare Sector # 383
Overall # 2683

Revenue TTM Y/Y Growth Statistics
High Average Low
242.68 %
4.96 %
-92.17 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 54
Sector # 102
S&P 500 # 401




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ABCL's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Intuitive Surgical Inc 32.71%$ 32.714 millions
Adc Therapeutics Sa32.20%$ 32.197 millions
Biomarin Pharmaceutical Inc32.02%$ 32.019 millions
The Pennant Group Inc 31.96%$ 31.965 millions
Beta Bionics Inc 30.92%$ 30.923 millions
Cadre Holdings inc 30.36%$ 30.362 millions
Krystal Biotech Inc 30.21%$ 30.206 millions
Sight Sciences Inc 29.83%$ 29.828 millions
Ge Healthcare Technologies Inc 29.41%$ 29.413 millions
Moderna Inc 29.23%$ 29.232 millions
Ani Pharmaceuticals Inc27.64%$ 27.638 millions
Geron Corporation27.45%$ 27.448 millions
Vericel Corporation26.47%$ 26.470 millions
Axogen inc 26.22%$ 26.218 millions
Cardio Diagnostics Holdings Inc 25.74%$ 25.744 millions
Edap Tms Sa25.55%$ 25.549 millions
Lifestance Health Group Inc 25.30%$ 25.303 millions
The Oncology Institute Inc 24.31%$ 24.313 millions
Vanda Pharmaceuticals Inc 24.10%$ 24.098 millions
Mannkind Corporation24.04%$ 24.035 millions
Castle Biosciences Inc 23.90%$ 23.901 millions
Prestige Consumer Healthcare Inc 22.93%$ 22.929 millions
Acadia Pharmaceuticals Inc 22.85%$ 22.847 millions
Veracyte Inc 22.10%$ 22.105 millions
Radnet Inc 22.07%$ 22.068 millions
Alkermes Plc 21.80%$ 21.804 millions
Alpha Teknova Inc 21.52%$ 21.523 millions
Orthopediatrics Corp20.55%$ 20.551 millions
Insulet Corporation19.21%$ 19.213 millions
Abcellera Biologics Inc 18.81%$ 18.805 millions


About Abcellera Biologics Inc Revenue Growth Rates (ABCL), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Abcellera Biologics Inc (CIK 1703057).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001703057-26-000059
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Abcellera Biologics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.